Physician profile
Esther Perlmutter
NPI 1356647861
$2,508.43
in general payments reported to CMS, 2019-2025
28 companies · $550 in 2025
The $550 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $391 · 2023: $614 · 2024: $723 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $349.11 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $305.01 | 2021-2025 | |
| Lilly USA, LLC | $279.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $216.12 | 2022-2024 | |
| Exact Sciences Corporation | $214.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $124.88 | 2021-2024 | |
| Novo Nordisk INC | $116.49 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $105.82 | 2021-2024 | Breztri, Farxiga |
| Shield Therapeutics INC | $103.80 | 2025 | |
| Amgen INC. | $89.50 | 2022-2025 | Krystexxa, Repatha |
| Insulet Corporation | $86.28 | 2025 | Omnipod |
| Averitas Pharma INC. | $68.82 | 2025 | Qutenza |
| Lundbeck LLC | $58.21 | 2022-2023 | Rexulti |
| Biogen, INC. | $55.84 | 2024 | Skyclarys |
| Baxter Healthcare | $43.11 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $40.61 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Novavax INC | $32.97 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Takeda Pharmaceuticals U.S.A., INC. | $29.81 | 2021-2022 | |
| Abbott Laboratories | $24.73 | 2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $23.60 | 2023 | Krystexxa |
| Noven Therapeutics, LLC | $22.78 | 2024 | Xelstrym |
| Philips North America LLC | $22.06 | 2025 | Ecc Solutions |
| Renalytix Ai, INC. | $19.58 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.37 | 2025 | Caplyta |
| Almatica Pharma LLC | $15.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2024 | Ajovy |
| Merck Sharp & Dohme LLC | $14.55 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.